Anti PD1 antibody has failed to improved survival of patients with advanced HCC in randomized controlled trials. This study analyzed the mechanisms of resistance to anti PD1 treatment using genetically engineered mouse models of HCC. They showed that activation of Wnt/B-catenin pathway explained resistance to immunotherapy which involved defective recruitment of dendritic cells and impaired T-cell activity.
(Ruiz de Galarreta M et al. – Cancer Discovery, August 2019)